Alpha Cognition Inc
ACOG
Rank in Stocks
#16947
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Share Price
$8.62
Last synced: 2026-11-11
Market Cap
$187.69M
Change (1 day)
-1.26%
Change (1 year)
45.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Alpha Cognition Inc (ACOG)
Category
Healthcare
EPS for Alpha Cognition Inc (ACOG)
EPS as of June 2026 TTM: $-1.09
According to Alpha Cognition Inc's latest financial reports, its current EPS (TTM) is $-1.09. At the end of 2025 the company had an EPS of $-1.17, an increase over its 2024 EPS of $-2.02.
EPS history for Alpha Cognition Inc from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.09 | -6.84% |
| 2025 | $-1.17 | -42.08% |
| 2024 | $-2.02 | -47.40% |
| 2023 | $-3.84 | -13.87% |
| 2022 | $-4.46 | -52.20% |
| 2021 | $-9.33 | 233.57% |
| 2020 | $-2.80 | 2.50% |
| 2019 | $-2.73 | 290.36% |
| 2018 | $-0.70 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,536.70% |
US
|
|
| $-7.07 | 548.62% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| $12.88 | -1,281.66% |
BE
|
|
| $21.56 | -2,077.98% |
NL
|
Questions about Alpha Cognition Inc's earnings per share (EPS)
What is Alpha Cognition Inc's earnings per share (EPS)?
Alpha Cognition Inc's earnings per share (EPS) over the last twelve months is $-1.09, as of Jun 2026.
What was Alpha Cognition Inc's earnings per share (EPS) in 2025?
In 2025, Alpha Cognition Inc's earnings per share (EPS) was $-1.17, compared with $-2.02 in 2024.
How has Alpha Cognition Inc's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Alpha Cognition Inc's earnings per share (EPS) was highest in 2025 ($-1.17) and lowest in 2021 ($-9.33).
How does Alpha Cognition Inc's earnings per share (EPS) compare with similar companies?
Alpha Cognition Inc's earnings per share (EPS) ($-1.09) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.